Drug Trial Radar · NCT06456359
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Dec 19, 2024
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- University Hospital HeidelbergAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 13 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) in young adults and adolsecents with male predominance. Current management of DSRCT and SySa includes chemotherapy, radiation and aggressive cytoreductive surgery. Despite advances in multimodal therapy, outcomes remain poor with frequent disease recurrence and very limited options for patients with advanced disease. Selected somatostatin receptor (SSTR) family members, i.e., SSTR2, SSTR3 and SSTR5, are frequently overexpressed in DSRCT and SySa, providing the rationale for treatment with somatostatin analogues (SSA). Pasireotide is a SSA with high affinity for SSTR1, -2, -3, and -5 and is approved for the treatment of Cushing's disease and acromegaly and has also shown activity in other cancers. In patients with advanced stage DSRCT and SySa, conventional chemotherapeutic approaches frequently lead to disease response, however, the duration of progression-free time after chemotherapy is short. The targeted approach with pasireotide after initial intensive multimodal treatment may have the potential to significantly improve outcome.
Conditions
- Desmoplastic Small Round Cell Tumor
- Synovial Sarcoma
Interventions
SigniforDrug
Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS)Time frame: PFS, measured from study registration to radiologically confirmed disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first up to 4 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
National Center for Tumour Diseases, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin
Stuttgart, Baden-Wurttemberg, Germany · Not yet recruiting
Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl
Stuttgart, Baden-Wurttemberg, Germany · Not yet recruiting
Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie
Essen, North Rhine-Westphalia, Germany · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.